Department of Internal Medicine and Division of Cardiology, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX, 75390-8830, USA.
Curr Cardiol Rep. 2020 Jul 9;22(9):87. doi: 10.1007/s11886-020-01331-z.
The purpose of this review is to discuss the updated guideline recommendations on management of dyslipidemia for prevention and treatment of cardiovascular disease.
The American College of Cardiology/American Heart Association (ACC/AHA) and European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) published revised cholesterol management guidelines in 2018 and 2019, respectively, to reflect new evidence in the field. Broadly speaking, both emphasize refining cardiovascular disease risk estimation and aggressively lowering low-density lipoprotein-cholesterol (LDL-C) with statin and non-statin agents to curb cardiovascular risk. While they share the same guiding principles, there are important differences in the recommendations from both societies including how they define risk categories and goals for LDL-C lowering. This review summarizes current methods of managing dyslipidemia with a focus on the common themes and notable differences between the 2018 ACC/AHA and 2019 ESC/EAS cholesterol management guidelines.
本综述旨在讨论血脂异常管理的最新指南建议，以预防和治疗心血管疾病。
美国心脏病学会/美国心脏协会（ACC/AHA）和欧洲心脏病学会/欧洲动脉粥样硬化学会（ESC/EAS）分别于 2018 年和 2019 年发布了修订后的胆固醇管理指南，以反映该领域的新证据。总体而言，两者都强调细化心血管疾病风险评估，并通过他汀类药物和非他汀类药物积极降低低密度脂蛋白胆固醇（LDL-C）以遏制心血管风险。虽然它们遵循相同的指导原则，但两个学会的建议存在重要差异，包括它们如何定义风险类别和 LDL-C 降低的目标。本综述总结了目前管理血脂异常的方法，重点关注 2018 年 ACC/AHA 和 2019 年 ESC/EAS 胆固醇管理指南之间的共同主题和显著差异。
